Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study

Autor: Cicchiello, F., Riva, F., Cazzaniga, M. E., Pedani, F., Nicolini, Matteo, Butti, C., Liscia, N., Pogliani, C., Capri, Giorgia, Alu', Matteo, Febbraro, A., Petrucelli, L., D'Onofrio, L., De Laurentiis, M., Pellegrini, D., Mentuccia, L., Cocciolone, V., Miraglio, E., Bajardi, E., Dester, M., Paternò, Enrico, Guaitoli, G., Ferrarini, I., Gervasi, Elisea, Licata, L., Benedetto, C., Andreis, D., Bordin, E., Ancona, C., Pizzuti, L., Fotia, V., Berardi, R., Airoldi, M., Arcangeli, V., Artale, S., Atzori, F., Ballerio, A., Bianchi, G. V., Blasi, L., Campidoglio, S., Ciccarese, M., Cursano, M. C., Piezzo, M., Fabi, A., Ferrari, L., Ferzi, A., Ficorella, C., Frassoldati, A., Fumagalli, A., Garrone, O., Gebbia, V., Generali, D., La Verde, N., Maur, M., Michelotti, A., Moretti, G., Musolino, Anna, Palumbo, R., Pistelli, M., Porpiglia, M., Sartori, D., Scavelli, C., Schirone, A., Turletti, A., Valerio, M. R., Vici, P., Zambelli, Ruggero Astolfo, Clivio, L., Torri, V.

Publikováno v: The Breast. 35:115-121

Background The BOLERO-2 trial reported efficacy and safety of Everolimus (EVE) and Exemestane (EXE) combination in HR+ advanced breast cancer (ABC) patients. The BALLET trial further evaluated the safety of EVE-EXE in HR+ ABC patients, without report

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e9c7bbed35067dbb46616b54e690e1e
https://doi.org/10.1016/j.breast.2017.06.043

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study

Autor: Conte, P., Frassoldati, A., Bisagni, G., Brandes, A. A., Donadio, M., Garrone, O., Piacentini, F., Cavanna, L., Giotta, F., Aieta, M., Gebbia, V., Molino, A., Musolino, A., Ferro, A., Maltoni, R., Danese, S., Zamagni, C., Rimanti, A., Cagossi, K., Russo, A., Pronzato, P., Giovanardi, F., Moretti, G., Lombardo, L., Schirone, A., Beano, A., Amaducci, L., Bajardi, E. A., Vicini, R., Balduzzi, S., D'Amico, R., Guarneri, Falci C, V., Giarratano, T, Mcmahon, L, De Salvo GL, Dieci, Mv, Maiorana, A, Ficarra, G, Caggia, F, Grisolia, D, Bartolini, S, Lorusso, V, Ardito, R, Tartarone, A, Vanella, P, Taverniti, C, Porpiglia, M, Spanu, Pg, Biglia, N, Andreis, D, Piancastelli, A, Fedeli, A, Parra, Hs, Gambaro, Ar, Romito, S, Malossi, A, Gori, S, Miglietta, L, Del Mastro, L, Amoroso, D, Mansutti, M, Generali, D, Prati, G, Bertolini, A, Berardi, R, Zanni, A, Cottafavi, L, Bologna, A, Naso, G, Pancotti, A, Farci, D, Zoboli, A, Silva, R, Laudadio, L, Bordonaro, R, Marenco, D, Dongiovanni, V, Baldini, E, Saggia, C, Gorzegno, G, Cariello, A, Biganzoli, L, Rampello, E.

Publikováno v: Annals of Oncology. 29:2328-2333

Background: Chemotherapy plus 1-year trastuzumab is the standard adjuvant treatment of HER2-positive breast cancer. The efficacy of less extended trastuzumab exposure is under investigation. The short-HER study was aimed to assess the non-inferiority

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b61f781b7e9350a5669985b12e94ae5c
https://doi.org/10.1093/annonc/mdy414

Marking of Target Lymph Nodes with carbon suspension in breast cancer patients undergoing neoadjuvant chemotherapy – first results from the AXSANA study (NCT04373655). (German)

Autor: Rief, A., Hartmann, S., Banys-Paluchowski, M., de Boniface, J., Gentlini, O. D., Stickeler, E., Karadeniz Cakmak, G., Hauptmann, M., Basali, T., Berger, T., Fröhlich, S., Ruf, F., Schmidt, E., Wihlfahrt, K., Aktas Sezen, B., Porpiglia, M., Zetterlund, L., Natsiopoulos, I., Sackey, H., Hadar, T.

Publikováno v: Senologie; Jun2024, Vol. 21 Issue 2, pe27-e27, 1p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

P202 Targeted axillary dissection after neoadjuvant chemotherapy: a multicenter prospective study of feasibility and safety.

Autor: Villasco, A., Minella, C., Borella, F., Panazzolo, G., Porpiglia, M., Castellano, I., Baù, M.G., Accomasso, F., Actis, S., Barbero, M., Benedetto, C., Biglia, N.

Publikováno v: Breast; 2023 Supplement, Vol. 68, pS95-S96, 2p